134 related articles for article (PubMed ID: 34819989)
21. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
22. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
23. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
[No Abstract] [Full Text] [Related]
24. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
28. The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer.
Pieper W; Ignatov A; Kalinski T; Haybaeck J; Czapiewski P; Nass N
Cancer Biomark; 2021; 32(2):161-173. PubMed ID: 34092612
[TBL] [Abstract][Full Text] [Related]
29. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Reitsamer R; Peintinger F; Prokop E; Hitzl W
Anticancer Drugs; 2005 Sep; 16(8):867-70. PubMed ID: 16096435
[TBL] [Abstract][Full Text] [Related]
30. Response to neoadjuvant chemotherapy in patients with advanced breast cancer: a local hospital experience.
Khokher S; Mahmood S; Khan SA
Asian Pac J Cancer Prev; 2010; 11(2):303-8. PubMed ID: 20843105
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer.
Götte M; Kersting C; Ruggiero M; Tio J; Tulusan AH; Kiesel L; Wülfing P
Anticancer Res; 2006; 26(1B):621-7. PubMed ID: 16739330
[TBL] [Abstract][Full Text] [Related]
32. Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome.
Moreno A; Escobedo A; Benito E; Serra JM; Gumà A; Riu F
Breast Cancer Res Treat; 2002 Sep; 75(2):119-25. PubMed ID: 12243504
[TBL] [Abstract][Full Text] [Related]
33. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
34. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.
Moon YW; Rha SY; Jeung HC; Yang WI; Suh CO; Chung HC
Ann Oncol; 2005 Nov; 16(11):1778-85. PubMed ID: 16091429
[TBL] [Abstract][Full Text] [Related]
36. Remission rates in breast cancer treated with preoperative chemotherapy and radiotherapy.
Gerlach B; Audretsch W; Gogolin F; Königshausen T; Rohn R; Schmitt G; Dimmerling P; Gripp S; Hartmann KA
Strahlenther Onkol; 2003 May; 179(5):306-11. PubMed ID: 12740657
[TBL] [Abstract][Full Text] [Related]
37. Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer.
Cakmakli S; Ersöz S; Tuğ T; Karaayvaz M; Akgül H
Acta Oncol; 1997; 36(5):489-92. PubMed ID: 9292745
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of response evaluation methods of neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Wu SK; Jiang ZF; Wang T; Zhang SH; Zhao YB; Yu CZ; Li XB; Yang T; Li GJ
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):783-5. PubMed ID: 20021835
[TBL] [Abstract][Full Text] [Related]
39. Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy.
Roth SL; Audretsch W; Bojar H; Lang I; Willers R; Budach W
Strahlenther Onkol; 2010 Jun; 186(6):299-306. PubMed ID: 20495968
[TBL] [Abstract][Full Text] [Related]
40. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
